In this article
One of red light therapy’s strongest selling points is its safety profile — minimal side effects, non-invasive, and generally well-tolerated. But this safety picture changes when certain medications are in the equation. Photosensitising drugs can amplify the skin’s response to light, potentially causing burns, blistering, or hyperpigmentation that would not occur without the medication.
This guide categorises common medications by their interaction risk with red light therapy, explains the underlying mechanism, and provides practical guidance for safe use.
How Photosensitisation Works
Photosensitisation occurs when a drug or its metabolites absorb light energy and transfer it to surrounding tissue, generating reactive oxygen species (ROS) or directly damaging cellular structures. There are two main types:
Phototoxic Reactions
Phototoxic reactions are dose-dependent and occur in anyone taking a sufficient dose of the offending drug when exposed to the relevant wavelengths of light. The drug molecule absorbs photon energy and generates ROS (primarily singlet oxygen and superoxide), which damage cell membranes, DNA, and proteins.
- Appearance: Exaggerated sunburn — redness, swelling, blistering, pain — confined to light-exposed areas
- Onset: Usually within hours of light exposure
- Wavelength dependence: Most phototoxic drugs absorb primarily in the UVA (320–400 nm) and UVB (280–320 nm) ranges, with some extending into visible violet/blue light (400–500 nm)
Photoallergic Reactions
Photoallergic reactions are immune-mediated. Light energy transforms the drug molecule into a hapten that binds to skin proteins, creating a neoantigen that triggers a delayed-type hypersensitivity response.
- Appearance: Eczematous dermatitis — itching, papules, vesicles — that may spread beyond light-exposed areas
- Onset: 24–72 hours after exposure
- Wavelength dependence: Similar to phototoxic reactions, primarily UVA-driven
The Red Light Question
Here is the critical nuance: most photosensitising drugs have peak absorption in the UV and short visible (blue/violet) wavelength ranges, not in the red or near-infrared spectrum used in photobiomodulation.
Red light therapy devices emit wavelengths of 630–670 nm (red) and 810–850 nm (near-infrared). These are substantially longer wavelengths than the UVA (320–400 nm) and blue/violet (400–500 nm) light that drives most photosensitivity reactions.
This means the risk profile of red light therapy with photosensitising medications is meaningfully different from, and generally lower than, the risk of sun exposure or UV-based light therapy (such as PUVA or narrowband UVB). However, “lower risk” is not “no risk,” and several medications warrant caution.
High-Risk Medications
These medications have strong photosensitising potential and require careful consideration before combining with red light therapy. In some cases, avoidance is recommended.
Tetracycline Antibiotics
| Drug | Brand Examples | Photosensitivity Risk | Notes |
|---|---|---|---|
| Doxycycline | Vibramycin, Oracea | Very high | Most photosensitising tetracycline |
| Minocycline | Minocin | Moderate | Can also cause blue-grey skin discolouration |
| Tetracycline | Achromycin | High | Less commonly prescribed now |
| Demeclocycline | Declomycin | Very high | Strongest photosensitiser in class |
Mechanism: Tetracyclines accumulate in the skin and absorb UVA/visible light energy, generating singlet oxygen that damages keratinocytes and melanocytes. Doxycycline is particularly problematic because its peak absorption extends into the visible spectrum (up to approximately 500 nm).
Red light therapy risk: The absorption spectrum of doxycycline does not significantly overlap with red (630–660 nm) or NIR (810–850 nm) wavelengths. Phototoxic reactions from pure red/NIR sources are theoretically unlikely. However:
- If the red light therapy device emits any shorter wavelengths (some cheaper devices have broader emission spectra), phototoxic reactions are possible
- Doxycycline increases overall skin sensitivity to oxidative stress, and PBM involves some degree of ROS modulation
- Recommendation: Proceed with caution. Use quality devices with narrow emission spectra. Start with lower energy densities (2–3 J/cm²) and monitor for any unusual redness or burning. Avoid treatment during peak drug concentration (2–4 hours after oral dose). If you experience any phototoxic symptoms, discontinue immediately.
Fluoroquinolone Antibiotics
| Drug | Brand Examples | Photosensitivity Risk |
|---|---|---|
| Ciprofloxacin | Ciproxin | Moderate |
| Levofloxacin | Tavanic | Moderate |
| Moxifloxacin | Avelox | Moderate-High |
| Ofloxacin | Tarivid | Moderate |
Mechanism: Fluoroquinolones absorb UVA and generate ROS, causing phototoxic reactions. Some fluoroquinolones (particularly those with a halogen at position 8) have absorption extending into the visible range.
Red light therapy risk: Low to moderate. Similar to tetracyclines, the primary absorption is in the UV/blue range, not red/NIR. The same precautions apply: use quality devices, start conservatively, and monitor the skin.
Isotretinoin (Accutane)
| Drug | Brand Examples | Photosensitivity Risk |
|---|---|---|
| Isotretinoin | Roaccutane, Accutane | Very high |
Mechanism: Isotretinoin dramatically thins the stratum corneum and increases transepidermal water loss, making the skin more vulnerable to all forms of energy-based treatment. It is not a traditional photosensitiser (it does not absorb light and generate ROS), but it renders the skin structurally fragile.
Red light therapy risk: Moderate to high. The concern is not photochemical (ROS generation) but structural — the thinned, compromised skin barrier may respond unpredictably to thermal and photochemical effects of PBM.
Recommendation: Most dermatologists recommend avoiding all energy-based skin treatments (laser, IPL, and red light therapy) during isotretinoin treatment and for 6–12 months after completion. This is a conservative recommendation, and the actual risk with low-power LED-based PBM may be lower than with ablative lasers, but the prudent approach is to follow your dermatologist’s guidance.
Methotrexate
| Drug | Brand Examples | Photosensitivity Risk |
|---|---|---|
| Methotrexate | Metoject, Maxtrex | Moderate-High |
Mechanism: Methotrexate causes photosensitivity through an incompletely understood mechanism, possibly involving phototoxic metabolites and reduced skin repair capacity (due to antifolate effects on rapidly dividing keratinocytes). “Radiation recall” reactions — reactivation of previous sunburn or radiation dermatitis — have been documented.
Red light therapy risk: Low to moderate for pure red/NIR wavelengths. The primary photosensitivity is UV-driven. However, methotrexate impairs wound healing and skin repair, which could affect recovery from any inadvertent over-treatment.
Recommendation: Use conservative energy densities (2–4 J/cm²). Do not treat areas of active skin inflammation or lesions (particularly relevant for psoriasis patients, who commonly take methotrexate).
Amiodarone
| Drug | Brand Examples | Photosensitivity Risk |
|---|---|---|
| Amiodarone | Cordarone X | Very high |
Mechanism: Amiodarone and its active metabolite desethylamiodarone accumulate in the skin (causing a characteristic blue-grey discolouration) and have an absorption spectrum that extends significantly into the visible light range — potentially up to 600+ nm. This makes amiodarone one of the few medications where photosensitivity may extend close to red light therapy wavelengths.
Red light therapy risk: Moderate. Amiodarone’s absorption spectrum extends further into the visible range than most photosensitisers, bringing it closer to the 630 nm wavelength used in red light therapy. Additionally, amiodarone has an extremely long half-life (40–55 days), meaning photosensitivity persists for months after discontinuation.
Recommendation: Avoid red light therapy while taking amiodarone, or proceed only under medical supervision. If treatment is attempted, use NIR wavelengths (810–850 nm) rather than red (630–660 nm), as the drug’s absorption is lower at longer wavelengths.
Moderate-Risk Medications
These medications have photosensitising potential but are less likely to interact problematically with red/NIR wavelengths specifically.
Topical Retinoids
| Drug | Brand Examples | Risk with RLT |
|---|---|---|
| Tretinoin (retinoic acid) | Retin-A, Differin (adapalene) | Moderate |
| Tazarotene | Zorac | Moderate |
| Retinol (cosmetic) | Various OTC | Low-Moderate |
Mechanism: Retinoids thin the stratum corneum and increase epidermal turnover, making the skin more sensitive to all forms of light and energy. They also increase free radical generation in UV-exposed skin.
Red light therapy risk: The thinned barrier may allow more light penetration than normal, and the increased cellular turnover makes skin more reactive. However, there is an ironic complementarity here: retinoids and red light therapy both promote collagen production and skin rejuvenation, and some dermatologists recommend using them together with appropriate spacing.
Recommendation:
- Do not apply topical retinoids immediately before red light therapy — allow at least 30 minutes between retinoid application and PBM, or use retinoids in the evening and PBM in the morning
- Start with lower energy densities (2–4 J/cm²) if you are in the first 4–6 weeks of retinoid use (when skin sensitivity is highest)
- Once your skin has acclimatised to the retinoid (typically 6–12 weeks), standard PBM protocols can usually be tolerated
NSAIDs
| Drug | Brand Examples | Risk with RLT |
|---|---|---|
| Piroxicam | Feldene | Moderate |
| Naproxen | Naprosyn, Aleve | Low-Moderate |
| Ketoprofen | Orudis | Moderate (topical) |
| Ibuprofen | Nurofen, Brufen | Low |
| Diclofenac | Voltarol | Low |
Mechanism: Some NSAIDs, particularly piroxicam and ketoprofen, are known photosensitisers that absorb UVA and generate phototoxic reactions. Others (ibuprofen, diclofenac) have minimal photosensitising potential.
Red light therapy risk: Low for most NSAIDs at red/NIR wavelengths. Piroxicam and ketoprofen (particularly topical formulations applied to the treatment area) warrant slightly more caution.
Recommendation: Standard red light therapy protocols are generally safe. If using topical ketoprofen or piroxicam, allow the product to absorb fully (at least 30 minutes) before treating the same area with PBM.
St John’s Wort (Hypericum perforatum)
| Supplement | Risk with RLT |
|---|---|
| St John’s Wort (oral) | Moderate |
| St John’s Wort (topical) | Moderate-High |
Mechanism: Hypericin, the active compound in St John’s Wort, is a potent photosensitiser with an absorption spectrum that extends into the visible range (around 550–600 nm). At high doses or with extensive sun exposure, clinical photosensitivity is well-documented.
Red light therapy risk: Moderate. Hypericin’s absorption peak is around 590–600 nm — close to but not overlapping with typical red LED emission at 630–660 nm. However, there is enough spectral proximity to warrant caution, particularly with topical application where local concentrations are high.
Recommendation: If taking St John’s Wort orally at standard doses (300 mg three times daily), the photosensitivity risk with red/NIR therapy is probably low. However, avoid applying St John’s Wort oil or cream to areas immediately before red light therapy treatment.
Low-Concern Medications
The following common medication categories have minimal or no expected interaction with red/NIR light therapy wavelengths:
| Category | Common Examples | Interaction Risk |
|---|---|---|
| SSRIs/SNRIs | Sertraline, fluoxetine, venlafaxine | Very low |
| Beta-blockers | Atenolol, bisoprolol, propranolol | Very low |
| ACE inhibitors | Ramipril, lisinopril, enalapril | Very low |
| Statins | Atorvastatin, simvastatin, rosuvastatin | Very low |
| Metformin | Glucophage | Very low |
| Paracetamol | Calpol, Panadol | None |
| Proton pump inhibitors | Omeprazole, lansoprazole | Very low |
| Thyroid hormones | Levothyroxine | None |
| Antihistamines | Cetirizine, loratadine, fexofenadine | Very low |
| Oral contraceptives | Various | Very low (melasma risk is hormonal, not photochemical) |
| Gabapentin/pregabalin | Neurontin, Lyrica | Very low |
| Antihypertensives (most) | Amlodipine, losartan, candesartan | Very low |
If you take any medication not listed here, the key question to ask your pharmacist or doctor is: “Does this medication cause photosensitivity?” If the answer is yes, the follow-up question is: “At what wavelengths?” Most photosensitising drugs act in the UV range and are unlikely to interact with red/NIR light therapy, but it is worth confirming.
Comprehensive Risk Table
| Medication | Drug Class | Photosensitivity | RLT Interaction Risk | Action |
|---|---|---|---|---|
| Doxycycline | Tetracycline antibiotic | Very High | Moderate | Use caution; lower dose; avoid peak concentration |
| Demeclocycline | Tetracycline antibiotic | Very High | Moderate | Same as doxycycline |
| Isotretinoin | Retinoid (systemic) | Very High | Moderate-High | Avoid during treatment + 6 months after |
| Amiodarone | Antiarrhythmic | Very High | Moderate-High | Avoid or use NIR only; medical supervision |
| Ciprofloxacin | Fluoroquinolone | Moderate | Low-Moderate | Proceed with caution |
| Methotrexate | Antimetabolite | Moderate-High | Low-Moderate | Lower energy density; avoid inflamed areas |
| Piroxicam | NSAID | Moderate | Low | Standard protocols usually fine |
| St John’s Wort | Herbal supplement | Moderate | Low-Moderate | Avoid topical application before RLT |
| Tretinoin (topical) | Retinoid (topical) | Moderate | Low-Moderate | Time-separate; start with lower doses |
| Hydrochlorothiazide | Thiazide diuretic | Moderate | Low | Standard protocols usually fine |
| Naproxen | NSAID | Low-Moderate | Low | Standard protocols usually fine |
| Ibuprofen | NSAID | Low | Very Low | No special precautions |
| SSRIs | Antidepressant | Very Low | Very Low | No special precautions |
| Metformin | Antidiabetic | None | None | No special precautions |
Practical Decision Framework
If you take a medication and want to use red light therapy, follow this framework:
Step 1: Check the Medication
Look up your medication in the tables above or ask your pharmacist whether it causes photosensitivity.
Step 2: Assess the Risk Level
- High risk (doxycycline, isotretinoin, amiodarone): Consult your prescribing doctor before starting red light therapy. Consider whether the medication course is temporary (e.g., a 2-week antibiotic course) — it may be simpler to pause PBM during the medication course
- Moderate risk (fluoroquinolones, methotrexate, topical retinoids, St John’s Wort): Proceed with precautions (see below)
- Low risk or no risk (most common medications): Proceed with standard protocols
Step 3: Apply Precautions (for Moderate and High Risk)
- Use quality devices — ensure your device has a narrow emission spectrum with no significant output below 620 nm
- Start low — begin with 2–3 J/cm² rather than standard 4–6 J/cm²
- Time your sessions — avoid red light therapy at peak drug concentration (typically 2–4 hours after an oral dose)
- Monitor carefully — inspect treated skin after the first 2–3 sessions for any unusual redness, burning, swelling, or pigmentation changes
- Patch test — if concerned, treat a small area (e.g., inner forearm) first and assess the response after 24–48 hours before treating larger areas or the face
- Separate topicals — if using topical retinoids, apply at least 30 minutes apart from PBM sessions, or use retinoids in the evening and PBM in the morning
Step 4: Know When to Stop
Discontinue red light therapy and consult your doctor if you experience:
- Unusual redness or burning that persists beyond a few hours after treatment
- Blistering or vesicle formation in treated areas
- New or worsened hyperpigmentation in treated areas
- Any rash or eczematous reaction developing 24–72 hours after treatment (possible photoallergic reaction)
Special Populations
Cancer Patients on Photosensitising Chemotherapy
Several chemotherapy drugs are photosensitising, including:
- 5-fluorouracil (5-FU)
- Dacarbazine
- Vemurafenib (strongly photosensitising)
- Vandetanib
Red light therapy is sometimes used for chemotherapy-related conditions (oral mucositis, neuropathy, wound healing). In these cases, treatment is typically delivered under medical supervision with appropriate wavelength and dose selection. Self-treatment with consumer devices during chemotherapy is not recommended without oncologist approval.
Patients on Multiple Medications
Polypharmacy increases complexity. If you take multiple medications with any degree of photosensitising potential, the cumulative effect may be greater than any single drug alone. This is particularly relevant in older adults who may take 5–10 medications simultaneously.
Recommendation: If you take three or more medications and any of them appear in the moderate or high-risk categories, consult your doctor or pharmacist before starting red light therapy.
The Bottom Line
The interaction between red light therapy and medications is more nuanced than either “completely safe” or “avoid entirely.” The key insight is that most drug-induced photosensitivity occurs at UV and short visible wavelengths (320–500 nm), which are substantially shorter than the red (630–660 nm) and near-infrared (810–850 nm) wavelengths used in photobiomodulation.
For most people on common medications, standard red light therapy protocols can be used without modification. For those on high-risk photosensitising drugs — particularly doxycycline, isotretinoin, and amiodarone — a cautious approach with medical guidance is warranted.
When in doubt, ask your prescribing doctor or pharmacist. Bring this article or the specific wavelength specifications of your device to the consultation — many clinicians are unfamiliar with the distinction between UV phototherapy and red/NIR photobiomodulation, and knowing the specific wavelengths involved helps them make an informed recommendation.
This article is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist about potential interactions between your medications and any new treatment, including red light therapy. Do not discontinue prescribed medications without medical guidance.
Related topics: red light therapy medication interactions · doxycycline and red light therapy · red light therapy and retinol
Find the right device
Compare 20+ red light therapy devices by wavelength, irradiance, and value.